Publication | Closed Access

A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker

Surgical OncologyGastrointestinal OncologyMedicinePhase Ii StudySurgeryMolecular OncologyCancer TreatmentPotential Chemoresistance MarkerOncologyRadiation OncologyNucleotide Excision RepairCancer Research